Superhydrophobic Array Devices for the Enhanced Formation of 3D Cancer Models
During the metastatic cascade, cancer cells travel through the bloodstream as circulating tumor cells (CTCs) to a secondary site. Clustered CTCs have greater shear stress and treatment resistance, yet their biology remains poorly understood. We therefore engineered a tunable superhydrophobic array device (SHArD). The SHArD-C was applied to culture a clinically relevant model of CTC clusters. Using our device, we cultured a model of cancer cell aggregates of various sizes with immortalized cancer cell lines. These exhibited higher E-cadherin expression and are significantly more capable of surviving high fluid shear stress-related forces compared to single cells and model clusters grown using the control method, helping to explain why clustering may provide a metastatic advantage. Additionally, the SHArD-S, when compared with the AggreWell 800 method, provides a more consistent spheroid-forming device culturing reproducible sizes of spheroids for multiple cancer cell lines. Overall, we designed, fabricated, and validated an easily tunable engineered device which grows physiologically relevant three-dimensional (3D) cancer models containing tens to thousands of cells.
Authors
- Tin Nguyen (ORCID: https://orcid.org/0000-0001-8001-9470)
- Dayrl P. Briggs (ORCID: https://orcid.org/0000-0002-3655-7551)
- Kalana W. Jayawardana
- Alberto Esteban‐Linares (ORCID: https://orcid.org/0000-0002-8637-2977)
- Alexandria T. Carter
- Maria Lopez‐Cavestany (ORCID: https://orcid.org/0000-0001-5358-3746)
- Noah T. Reckhorn
- Dmitry S. Koktysh
- Deyu Li (ORCID: https://orcid.org/0000-0001-8364-0924)
- Michael R. King
- Olivia A. Wright
Institutions
- Oak Ridge National Laboratory (US)
- Vanderbilt University (US)
- Rice University (US)
Publication Details
- Journal
- ACS Nano
- Published
- 2024-08-16
- DOI
- https://doi.org/10.1021/acsnano.4c08132
- Citations
- 9
- Primary Topic
- 3D Printing in Biomedical Research
- Type
- article
- Field-Weighted Citation Impact
- 1.66
Funders
- National Cancer Institute